ABSTRACT
Angiotensinogen (AGT) is the unique substrate of all angiotensin peptides. We review the recent preclinical research of AGT antisense oligonucleotides (ASOs), a rapidly evolving therapeutic approach. The scope of the research findings not only opens doors for potentially new therapeutics of hypertension and many other diseases, but also provides insights into understanding critical physiological and pathophysiological roles mediated by AGT.
Subject(s)
Angiotensinogen/genetics , Antihypertensive Agents/pharmacology , Genetic Therapy/methods , Hypertension/therapy , Oligonucleotides, Antisense/genetics , Renin-Angiotensin System/genetics , Angiotensinogen/antagonists & inhibitors , Angiotensinogen/metabolism , Animals , Blood Pressure , Disease Models, Animal , Drug Evaluation, Preclinical , Humans , Hypertension/genetics , Hypertension/metabolism , Hypertension/physiopathology , Kidney/metabolism , Liver/metabolism , Molecular Targeted Therapy , Oligonucleotides, Antisense/chemical synthesis , Oligonucleotides, Antisense/metabolism , Rats, Inbred SHRABSTRACT
Cephalantheropsis gracilis afforded five new compounds: cephalanthrin-A (1), cephalanthrin-B (2), cephathrene-A (3), cephathrene-B (4), methyl 2-(aminocarbonyl) phenylcarbamate (5), and 52 known compounds. The structures of the new compounds were determined by spectroscopic analysis. Among the compounds isolated, tryptanthrin (6), phaitanthrin A (7), cephalinone D (19), and flavanthrin (30) showed significant cytotoxicity against MCF-7, NCI-H460, and SF-268 cell lines.